- Home
- RDHL vs CERO Comparison
RDHL vs CERO Comparison
Compare RDHL & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- CERO
- Stock Information
- Founded
- RDHL 2009
- CERO 2017
- Country
- RDHL Israel
- CERO United States
- Employees
- RDHL N/A
- CERO N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- CERO
- Sector
- RDHL Health Care
- CERO
- Exchange
- RDHL Nasdaq
- CERO Nasdaq
- Market Cap
- RDHL 4.3M
- CERO 3.5M
- IPO Year
- RDHL N/A
- CERO N/A
- Fundamental
- Price
- RDHL $2.15
- CERO $8.90
- Analyst Decision
- RDHL
- CERO Strong Buy
- Analyst Count
- RDHL 0
- CERO 2
- Target Price
- RDHL N/A
- CERO $45.00
- AVG Volume (30 Days)
- RDHL 18.2K
- CERO 3.3M
- Earning Date
- RDHL 08-28-2025
- CERO 08-13-2025
- Dividend Yield
- RDHL N/A
- CERO N/A
- EPS Growth
- RDHL N/A
- CERO N/A
- EPS
- RDHL N/A
- CERO N/A
- Revenue
- RDHL $8,042,999.00
- CERO N/A
- Revenue This Year
- RDHL $381.91
- CERO N/A
- Revenue Next Year
- RDHL N/A
- CERO N/A
- P/E Ratio
- RDHL N/A
- CERO N/A
- Revenue Growth
- RDHL 23.17
- CERO N/A
- 52 Week Low
- RDHL $1.71
- CERO $6.71
- 52 Week High
- RDHL $20.28
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- RDHL 64.10
- CERO 46.23
- Support Level
- RDHL $2.00
- CERO $8.50
- Resistance Level
- RDHL $2.08
- CERO $9.73
- Average True Range (ATR)
- RDHL 0.09
- CERO 1.20
- MACD
- RDHL 0.03
- CERO -0.01
- Stochastic Oscillator
- RDHL 100.00
- CERO 14.54
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.